Background: Pharmaceuticals have made an important contribution to global reductions in
morbidity and mortality. To help save lives and improve health, it is important to be sure about
equity to access to drugs, drug efficacy, quality and safety, and rational use of drugs, which are
standardized National Drug Policy (NDP) objectives. NDP's indicators are useful to evaluate the
pharmaceutical system performance in a country. Iran has adapted a National Drug List (NDL).
Since management of drug supply in Iran takes place only for drugs that have been selected in NDL
and this list is selected by the member of Iran Drug Selecting Committee (IDSC), thus evaluation
of IDSC's decision making during last 5 years is an appropriate way to evaluate the implementation
of drug supply system in the country.